How to treat first relapse in lenalidomide-refractory MM?

During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Clifton C. Mo and Omar Nadeem, Dana-Farber Cancer Institute, Boston, US. We asked, How to treat first relapse in lenalidomide-refractory multiple myeloma (MM)?In this podcast, Mo and Nadeem discuss factors to be considered with regimen options for patients with lenalidomide-refractory MM. They discuss cardiac risk factors, lines of therapy, prognosis, and end the podcast on the topic of new agents. Hosted on Acast. See acast.com/privacy for more information.

Om Podcasten

Guided by an international Steering Committee of world experts in Multiple Myeloma (MM), the MM Hub is a global online resource providing key information on Multiple Myeloma for hematologists, oncologists and researchers, run in collaboration with the European School of Haematology (ESH). Our mission is to provide the latest global up-to-date clinical guidance in Multiple Myeloma, through a comprehensive coverage of evidence-based literature, drug approvals, case studies, expert opinions and international congress reports. Hosted on Acast. See acast.com/privacy for more information.